TherapeuticsMD (TXMD) EBITDA Margin (2011 - 2026)
TherapeuticsMD's (TXMD) quarterly EBITDA Margin came in at 99.86% in Q1 2026, up 22609.0% YoY from N/an in Q1 2025, and up 42.54% on a QoQ basis from 173.8% in Q4 2025.
TherapeuticsMD (TXMD) EBITDA Margin (2011 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 16 years of EBITDA Margin data on file, last reported at 99.86% in Q1 2026.
- Quarterly EBITDA Margin rose 22609.0% year-over-year to 99.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 114.29% (up 20380.0% YoY) and the FY2025 annual result came in at 145.27%, up 20181.0% from the prior year.
- EBITDA Margin grew to 99.86% in Q1 2026, from 173.8% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 70.65% in Q4 2022 to a low of 4188.22% in Q2 2022.
- A 5-year average of 1054.43% and a median of 343.5% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin plunged 403527 bps — and 2023, when it jumped 365183 bps.
- Tracing TXMD's EBITDA Margin over 5 years: stood at 70.65% in 2022, then plunged by 586 bps to 343.5% in 2023, then jumped by 72 bps to 97.75% in 2024, then tumbled by 78 bps to 173.8% in 2025, then surged by 43 bps to 99.86% in 2026.
- The last three EBITDA Margin figures came in at 99.86% (Q1 2026), 173.8% (Q4 2025), and 109.95% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | TherapeuticsMD | 23.54 Mn | 14.35 Mn | - | -93.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -93.90% |
| Mar 31, 2026 | -99.86% |
| Dec 31, 2025 | -173.80% |
| Sep 30, 2025 | -109.95% |
| Jun 30, 2025 | -73.00% |
| Mar 31, 2025 | -325.95% |
| Dec 31, 2024 | -97.75% |
| Sep 30, 2024 | -207.31% |
| Jun 30, 2024 | -1,191.88% |
| Mar 31, 2024 | -364.86% |
| Dec 31, 2023 | -343.50% |
| Sep 30, 2023 | -3,100.00% |
| Jun 30, 2023 | -536.38% |
| Mar 31, 2023 | -634.62% |
| Dec 31, 2022 | 70.65% |
| Sep 30, 2022 | -4,024.29% |
| Jun 30, 2022 | -4,188.22% |
| Mar 31, 2022 | -2,524.60% |
| Dec 31, 2021 | -189.48% |
| Sep 30, 2021 | -157.13% |